Resistance to cabazitaxel, used to treat metastatic castration-resistant prostate cancer in combination with prednisone [221], is mediated by the UPR signaling pathways [222] IRE1α and PERK [223], although the underlying mechanisms behind the feedback loop remain unclear. Here, EIF2AK3 is linked to prostate carcinoma.